C4 Therapeutics Ownership | Who Owns C4 Therapeutics?

Overview Forecast RevenueFinancials Chart

C4 Therapeutics Ownership Summary

C4 Therapeutics is owned by 6.79% institutional investors, 7.20% insiders, and 86.01% retail investors. Morgan stanley is the largest institutional shareholder, holding 12.38% of CCCC shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.01% of its assets in C4 Therapeutics shares.

CCCC Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	C4 Therapeutics	6.79%	7.20%	86.01%
Sector	Healthcare Stocks	232.64%	10.66%	-143.30%
Industry	Biotech Stocks	382.13%	10.41%	-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Morgan stanley	8.98M	12.38%	$17.15M
Lynx1 capital management lp	7.10M	10.00%	$15.76M
Orbimed advisors	5.24M	7.37%	$11.62M
Blackrock	4.55M	6.61%	$21.03M
Vanguard group	4.38M	6.04%	$8.37M
Wasatch advisors lp	4.34M	5.99%	$8.30M
Soleus capital management	3.80M	5.24%	$7.27M
Silverarc capital management	1.99M	2.75%	$3.81M
Blackrock funding, inc. /de	1.97M	2.71%	$3.76M
Bank of america corp /de/	1.77M	2.57%	$8.17M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Lynx1 capital management lp	7.10M	3.21%	$15.76M
Silverarc capital management	1.99M	0.53%	$3.81M
Orbimed advisors	5.24M	0.27%	$11.62M
Soleus capital management	3.80M	0.27%	$7.27M
Bain capital life sciences investors	1.11M	0.16%	$2.47M
Intrepid family office	70.00K	0.13%	$155.40K
Shay capital	420.00K	0.08%	$932.40K
Vienna powszechne towarzystwo emerytalne s.a. vienna insurance group	85.00K	0.08%	$162.35K
Tang capital management	900.00K	0.08%	$2.00M
Wasatch advisors lp	4.34M	0.05%	$8.30M

Top Buyers

Holder	Shares	% Assets	Change
Morgan stanley	8.98M	0.00%	4.01M
Blackrock	4.55M	0.00%	3.65M
Vanguard group	4.38M	0.00%	1.19M
Jane street group	874.79K	0.00%	671.23K
Renaissance	1.60M	0.00%	665.63K

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-4.88M
Commodore capital lp	-	-	-3.41M
Soleus capital management	3.80M	0.27%	-3.25M
Samlyn capital	-	-	-3.02M
Orbimed advisors	5.24M	0.27%	-1.60M

New Positions

Holder	Shares	% Assets	Change	Value
Qube research	115.97K	0.00%	115.97K	$257.46K
Algert global	106.30K	0.00%	106.30K	$236.00K
Marshall wace, llp	106.28K	0.00%	106.28K	$235.93K
Graham capital management	40.63K	0.00%	40.63K	$90.19K
Connor, clark & lunn investment management	37.72K	0.00%	37.72K	$72.05K

Sold Out

Holder	Change
Ifp advisors	-17.00
Gradient investments	-25.00
True wealth design	-31.00
Coldstream capital management	-52.00
Capital performance advisors llp	-54.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	18	-82.52%	4,929,202	-90.62%	6	0.12%	9	-82.35%	6	-82.86%
Sep 30, 2025	21	-78.79%	4,095,962	-91.57%	5	0.12%	9	-83.33%	9	-72.73%
Jun 30, 2025	100	-13.04%	54,689,267	-14.68%	77	0.90%	55	-19.12%	33	17.86%
Mar 31, 2025	6	-95.20%	21,025,800	-67.35%	30	0.35%	4	-93.85%	1	-96.97%
Dec 31, 2024	122	-5.43%	64,367,933	0.29%	92	1.09%	63	-7.35%	33	3.13%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	2.14M	3.01%	-
Vanguard Total Stock Mkt Idx Inv	2.89M	2.98%	-
Wasatch Ultra Growth	2.83M	2.92%	-289.22K
SPDR® S&P Biotech ETF	1.57M	2.22%	22.34K
iShares Russell 2000 ETF	1.53M	2.16%	-
Wasatch Micro Cap	758.27K	1.07%	-483.88K
Vanguard Institutional Extnd Mkt Idx Tr	882.93K	0.91%	-
Fidelity Small Cap Index	623.59K	0.88%	-8.75K
Biotech Growth Ord	770.91K	0.80%	-471.81K
iShares Russell 2000 Value ETF	560.98K	0.79%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jan 16, 2026	REYNO LEONARD	Chief Medical Officer	Sell	$22.20K
Feb 18, 2025	Boyle Scott N	Chief Business Officer	Sell	$2.11K
Feb 14, 2025	Boyle Scott N	Chief Business Officer	Sell	$1.54K
Feb 08, 2023	Koppikar Utpal	-	Buy	$31.74K
Apr 12, 2022	Hirsch Andrew	President & CEO	Buy	$84.00K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	1
2025 Q4	-	-
2025 Q3	-	-
2025 Q2	-	-
2025 Q1	-	2

CCCC Ownership FAQ

Who Owns C4 Therapeutics?

C4 Therapeutics shareholders are primarily institutional investors at 6.79%, followed by 7.20% insiders and 86.01% retail investors. The average institutional ownership in C4 Therapeutics's industry, Biotech Stocks , is 382.13%, which C4 Therapeutics falls below.

Who owns the most shares of C4 Therapeutics?

C4 Therapeutics’s largest shareholders are Morgan stanley (8.98M shares, 12.38%), Lynx1 capital management lp (7.1M shares, 10.00%), and Orbimed advisors (5.24M shares, 7.37%). Together, they hold 29.75% of C4 Therapeutics’s total shares outstanding.

Does Blackrock own C4 Therapeutics?

Yes, BlackRock owns 6.61% of C4 Therapeutics, totaling 4.55M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 21.03M$. In the last quarter, BlackRock increased its holdings by 3.65M shares, a 402.93% change.

Who is C4 Therapeutics’s biggest shareholder by percentage of total assets invested?

Lynx1 capital management lp is C4 Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.21% of its assets in 7.1M C4 Therapeutics shares, valued at 15.76M$.

Who is the top mutual fund holder of C4 Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of C4 Therapeutics shares, with 3.01% of its total shares outstanding invested in 2.14M C4 Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools